ClinicalTrials.gg
RecruitingNCT07444281Updated Mar 3, 2026

An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer

A Phase 1 interventional study of C-CAR031 in Squamous Cell Lung Cancer, sponsored by Shanghai AbelZeta Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Shanghai AbelZeta Ltd. (part of AbelZeta Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2024, registered Feb 2026).
  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 847 studies in Lung Neoplasms with a site in China — 374 open to participants now, 421 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
499th of 588
24 · median 90
Started
2024
with 112 others
Phase 1
75 of 847
44 open now
Primary completion
2027-04
later than 250 of 420 live
Registered
760th of 847
by date

Among the 847 studies in Lung Neoplasms with a site in China, this one is the 499th largest by planned enrollment of the 588 interventional ones that give a count, is one of 113 that started in 2024, is one of 75 in phase 1, reaches primary completion later than 250 of the 420 other live ones, and was the 760th registered.

Lung Neoplasms

5,432 studies on the registry are indexed under Lung Neoplasms; 1,348 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

374 of the 847 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

369 more — sign in →

All 374 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 996 Lung Neoplasms studies recruiting now, 685 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 847 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

This single-arm, open-label, multicenter, Phase I study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK)/pharmacodynamics (PD), biomarker, and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/metastatic squamous cell lung cancer, who are not amenable to curative therapy and have progressed or are intolerant to no more than 3 lines of prior systemic treatment including immune checkpoint inhibitors (CPIs) and platinum-based doublet chemotherapy, concurrently or sequentially.

03

Conditions studied

  • Squamous Cell Lung Cancer

Browse trials for

Keywords

  • squamous cell lung cancer
  • advanced squamous cell lung cancer
  • metastatic squamous cell lung cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed unresectable Stage IIIB ,IIIC or IV squamous cell lung cancer
  • Confirmed to express GPC3, as assessed by immunohistochemistry at a central lab
  • Participants who have progressed or intolerant to no more than three lines of prior systemic therapies for advanced/ squamous cell lung cancer
  • At least one measurable target lesion
  • The (LVEF) measured by echocardiography ≥50% and reported as non-impaired.
  • Sufficient pulmonary function
  • The laboratory testing results meet the study requirements
  • Female participants of must test negative for pregnancy in serum or urine. Non-sterilized participants (males and females) agree to take effective measures for at least 12 months and until CAR-T below lower limit of detection (LLOD) by PCR which occurs last after C-CAR031 infusion.

Exclusion criteria

Exclusion Criteria:

  • known to harbor a driver mutation for which targeted standard therapy is recommended in accordance with local treatment guidelines.
  • Known life-threatening allergies, , or intolerance to the CAR-T product or its , including dimethyl sulfoxide (DMSO)
  • to lymphodepleting agents, including fludarabine and/or cyclophosphamide.
  • History of splenectomy or organ transplantation
  • Prior treatment with Any CAR-T therapy OR any therapy that is targeting GPC3
  • Uncontrolled or intercurrent pulmonary disease
  • ascites
  • Uncontrolled pleural effusion or pericardial effusion requiring recurrent drainage procedures
  • Cancer-related spinal cord compression, , or
  • Received radiation therapy, local treatment, vaccine, blood transfusion, systemic treatment within certain period of apheresis required by study protocol
  • History of or with active diseases or conditions of that's defined in study protocol
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    C-CAR031 Cohort 1

    Dose Level 1 at 0.75mpk C-CAR031 to be infused to subjects

    Drug: C-CAR031

  • Experimental
    C-CAR031 Cohort 2

    Dose Level 2 at 1.5mpk C-CAR031 to be infused to subjects

    Drug: C-CAR031

  • Experimental
    C-CAR031 Cohort 3

    Dose Level 3 at 4.0mpk C-CAR031 to be infused to subjects

    Drug: C-CAR031

Interventions

  • DrugC-CAR031

    C-CAR031 is an autologous CAR T-cell product that expresses a CAR specific for GPC3 and a dominant-negative transforming growth factor-beta receptor II (dnTGFβRII).

06

What researchers measure

Primary outcomes

  1. AE/SAE/AESI, DLT

    * To assess the safety and tolerability of C-CAR031 in participants * To determine the RDE (Phase Ia)

    Time frame: From baseline to 28 days after treatment

Secondary outcomes

  1. ORR (Objective Response Rate)

    To estimate the anti-tumor activity of C-CAR031 in participants with GPC3+ advanced/metastatic squamous cell lung cancer

    Time frame: From baseline until disease progression likely at 12 months

  2. CK Parameter and Quantification of CAR copies/μg DNA of C-CAR031

    To investigate the CK of C-CAR031

    Time frame: From baseline until 15 years of infusion as longest

  3. Presence of RCL

    To assess the safety of C-CAR031

    Time frame: From baseline until 15 years of infusion as longest

  4. DCR (Disease Control Rate)

    To estimate the anti-tumor activity of C-CAR031 in participants with GPC3+ advanced/metastatic squamous cell lung cancer

    Time frame: From baseline until disease progression likely at 12 months after treatment

  5. DoR (Duration of Response)

    Time frame: From baseline until disease progression likely at 12 months after treatment

  6. DRR (Durable Response Rate)

    Time frame: From baseline until disease progression likely at 12 months after treatment

  7. TTR (Time to Response)

    Time frame: From baseline until disease progression likely at 12 months after treatment

  8. PFS (Progression-free Survival)

    Time frame: From baseline until disease progression likely at 12 months after treatment

  9. Change in tumor size

    Time frame: From baseline until disease progression likely at 12 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Apr 2027, 28 months after the start.

Of 129 industry-sponsored phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 28 months is below that.

Counting every sponsor, half of 293 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Mar 2, 2026
StartActual
Dec 25, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jan 30, 2028
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444281
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Dec 25, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Mar 3, 2026

Study contacts

Yinghua Shen
Contact
yinghua.shen@abelzeta.com
+86-18616644879
Shun Lu, MD
principal investigator · Shanghai Chest Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion